Natarajan Sethuraman

Natarajan Sethuraman, PhD, is the Chief Scientific Officer of Entrada Therapeutics.

Prior to this role, Dr. Sethuraman was Executive Director and the GlycoFi Site Head at Merck. At Merck, Dr. Sethuraman was responsible for the development of GlycoFi’s glyco-engineered platform for differentiated biologics. He was also part of the Biologics Discovery leadership team at Merck Research Laboratories which set the strategy and prioritization of all Merck biologics. Dr. Sethuraman came to Merck through its acquisition of GlycoFi in 2006. At GlycoFi, Dr. Sethuraman was responsible for all downstream process development and preclinical studies as well as serving as the key scientific liaison for many of GlycoFi’s collaborations.

Dr. Sethuraman holds a BSc from Tamil Nadu Agricultural University and a PhD in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute. He received his post-doctoral training at Duke University where he worked on the elucidation of the termination of DNA replication in E. coli.